Dec 17, 2021 / 01:30PM GMT
Operator
Good day, everyone, and welcome to Pfizer's Analyst and Investor Call to discuss the Pfizer-BioNTech COVID-19 vaccine and Pfizer's novel COVID-19 oral antiviral treatment candidate. Today's call is being recorded.
At this time, I would like to turn the call over to Mr. Chris Stevo, Senior Vice President and Chief Investor Relations Officer. Please go ahead, sir.
Christopher J. Stevo - Pfizer Inc. - Senior VP & Chief IR Officer
Thank you, Sophia. Good morning, everyone. I'd like to welcome you all to Pfizer's investor event to discuss our COVID-19 vaccines and therapeutics franchise.
Presentation at today's investor event includes forward-looking statements about, amongst other things, our efforts to combat COVID-19, including our development of a vaccine to help prevent COVID-19 and our investigational protease inhibitors, our anticipated future operating and financial performance, business plans and prospects and expectations for our in-line products and product candidates.
By their nature, all statements about future events and
Pfizer Inc Analyst and Investor Call to Discuss Pfizer-BioNTech COVID-19 Vaccine and Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Transcript
Dec 17, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers